Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-29

Clinical Trial Update: Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OC-01 nasal spray for stimulation of goblet cells and meibomian glands in dry eye disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OC-01 Nasal Spray (varenicline)

Snippet

Sponsor: Oyster Point Pharma, Inc. | Conditions: Dry Eye Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-12-29